The epilepsy drugmaker reported record quarterly earnings as Xcopri U.S. sales surged and it set up dedicated IP and lifecycle teams to defend exclusivity ahead of the drug's 2032 core patent expiry.
SK Biopharmaceuticals reported record second-quarter earnings on August 5, driven by strong U.S. growth for epilepsy treatment Xcopri, while also strengthening patent and lifecycle management for the drug that the company said generates about 90% of revenue. Consolidated revenue rose 40.3% year over year to 247.4 billion won and operating profit climbed 56.9% to 97.1 billion won, with net income of 85.1 billion won. U.S. Xcopri revenue reached 224.4 billion won, up 45.6% from a year earlier, as the company pursued additional FDA filings for new formulations and broader indications, expanded marketing, and prepared for the October 2032 expiry of Xcopri's U.S. composition-of-matter patent. Industry sources said SK Biopharmaceuticals has separated its intellectual property function from legal and activated a lifecycle management team to extend cenobamate's long-term value, including through a method-of-use patent listed until June 2039, even as generic and competitive threats begin to emerge.